Sunitinib-containing carborane pharmacophore with the ability to inhibit tyrosine kinases receptors FLT3, KIT and PDGFR-β, exhibits powerful in vivo anti-glioblastoma activity

Malignant gliomas are the most common malignant and aggressive primary brain tumors in adults, the prognosis being—especially for glioblastomas—extremely poor. There are no effective treatments yet. However, tyrosine kinase receptor (TKR) inhibitors and boron neutron capture therapy (BNCT), together...

Full description

Bibliographic Details

Main Author:	Alamón, Catalina (author)
Other Authors:	Dávila Saralegui, Belén (author), García Melián, María Fernanda (author), Sánchez, Carina (author), Kovacs, Mariángeles (author), Trias, Emiliano (author), Barbeito, Luis (author), Gabay, Martín (author), Zeineh, Nidal (author), Gavish, Moshe (author), Teixidor, Francesc (author), Viñas, Clara (author), Couto, Marcos (author), Cerecetto, Hugo (author)
Format:	article
Language:	English
Published:	2020
Subjects:	Carborane FLT3 Sub-G1 arrest Anti-tumor activity
Online Access:	https://hdl.handle.net/20.500.12008/31990
Tags:	Add Tag No Tags, Be the first to tag this record!